---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-007900"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:39:14.750872+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics reports FY2022 revenue of $34.2M, down 65% YoY; net loss $0.45/share

## Summary
- Revenue $34.2M, down from $97.9M in 2021 due to lower COVID-19 test demand.
- Net loss $14.2M ($0.45 diluted EPS) vs net income $36.7M ($1.23) prior year.
- Operating loss $27.0M, driven by lower revenue, goodwill impairment, R&D for Co-Dx PCR Home.
- Adjusted net income (excl. goodwill) $1.2M, or $0.04 per diluted share.
- Initiated clinical evaluations for Co-Dx PCR Home platform; cash $81.3M.

## SEC filing metadata
- accession: 0001493152-23-007900
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315223007900/0001493152-23-007900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315223007900/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-007900
- JSON: https://secwatch.observer/filing/0001493152-23-007900.json
- Plain text: https://secwatch.observer/filing/0001493152-23-007900.txt

## Key facts
- Earnings Releases
  Co-Diagnostics, Inc. reported the full year ended December 31, 2022 results: revenue $34.2 million, net income $14.2 million, EPS $0.45 per fully diluted share.
  - Period: the full year ended December 31, 2022
  - Revenue: $34.2 million
  - Net income: $14.2 million
  - EPS: $0.45 per fully diluted share
  - Result: reported results
  source text: the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022. Full Year 2022 Financial Results: ● Revenue of $34.2 million, down from $97.9 million during the prior year primarily due to lower global demand for the Logix SmartTM COVID-19 tests ● Gross profit of $28.7 million, representing 84.0% of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1692415/000149315223007900/0001493152-23-007900-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.